In a study comparing rates of adverse events with filgrastim vs sargramostim (rHuGM-CSF) when given prophylactically to patients receiving myelosuppressive chemotherapy, 490 patients treated for lung, breast, lymphatic system, or ovarian tumors were analyzed. The frequency and severity of adverse events were assessed. Fever unexplained by infection was more common with sargramostim (7% vs 1%; p < 0.001), as were fatigue and diarrhea; however, skeletal pain was more frequent with filgrastim. Overall, adverse events were less frequent with filgrastim than with sargramostim (40).
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.